‘Low‐risk’ myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro‐ versus anti‐apoptotic bcl‐2‐related proteins
We performed flow cytometric analysis of CD34+ cell apoptosis in 59 patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) secondary to MDS (MDS‐AML) using annexin V‐FITC, which binds to exposed phosphatidylserine on apoptotic cells. Apoptosis was significantly increased in FA...
Saved in:
Published in: | British journal of haematology Vol. 103; no. 4; pp. 1075 - 1082 |
---|---|
Main Authors: | , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Oxford, U.K. and Cambridge, USA
Blackwell Science Ltd
01-12-1998
Blackwell |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | We performed flow cytometric analysis of CD34+ cell apoptosis in 59 patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) secondary to MDS (MDS‐AML) using annexin V‐FITC, which binds to exposed phosphatidylserine on apoptotic cells. Apoptosis was significantly increased in FAB subtypes RA, RARS and RAEB (<10% blasts) (56.5% (15.1–86.5%)) compared to normal controls (18.5% (3.4–33.4%), P < 0.0001) and RAEB‐t/MDS‐AML (16% (2.1–43.2%), P < 0.0001). There was no correlation between % apoptosis, Full blood count or cytogenetics in any disease category. Two‐colour cytometric analysis of permeabilized CD34+ cells stained with antibodies to Bcl‐2, Bcl‐X (anti‐apoptotic), Bax and Bad (pro‐apoptotic), demonstrated significantly higher ratios of pro‐ v anti‐apoptotic proteins in early MDS (2.47 (1.19–9.42) compared to advanced disease (1.14 (0.06–3.32), P = 0.0001). Moreover, using repeated measures of variants (ANOVA), we found that variations between individual Bcl‐2‐related proteins differed significantly according to disease subtype (P < 0.0005). Our results confirm that CD34+ cell apoptosis was significantly increased in MDS subtypes RA and RARS and fell with disease progression. Early MDS was also associated with a significantly higher CD34+ cell pro‐ v anti‐apoptotic Bcl‐2‐family‐protein ratio than advanced disease. Furthermore, patterns of expression of individual Bcl‐2 related proteins differed significantly between different disease categories. However, no correlation between pro‐ v anti‐apoptotic Bcl‐2‐family‐protein ratios and the degree of apoptosis was observed. |
---|---|
AbstractList | We performed flow cytometric analysis of CD34+ cell apoptosis in 59 patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) secondary to MDS (MDS-AML) using annexin V-FITC, which binds to exposed phosphatidylserine on apoptotic cells. Apoptosis was significantly increased in FAB subtypes RA, RARS and RAEB (<10% blasts) (56.5% (15.1-86.5%)) compared to normal controls (18.5% (3.4-33.4%), P<0.0001) and RAEB-t/MDS-AML (16% (2.1-43.2%), P<0.0001). There was no correlation between % apoptosis, Full blood count or cytogenetics in any disease category. Two-colour cytometric analysis of permeabilized CD34+ cells stained with antibodies to Bcl-2, Bcl-X (anti-apoptotic), Bax and Bad (pro-apoptotic), demonstrated significantly higher ratios of pro- v anti-apoptotic proteins in early MDS (2.47 (1.19-9.42) compared to advanced disease (1.14 (0.06-3.32), P=0.0001). Moreover, using repeated measures of variants (ANOVA), we found that variations between individual Bcl-2-related proteins differed significantly according to disease subtype (P<0.0005). Our results confirm that CD34+ cell apoptosis was significantly increased in MDS subtypes RA and RARS and fell with disease progression. Early MDS was also associated with a significantly higher CD34+ cell pro- v anti-apoptotic Bcl-2-family-protein ratio than advanced disease. Furthermore, patterns of expression of individual Bcl-2 related proteins differed significantly between different disease categories. However, no correlation between pro- v anti-apoptotic Bcl-2-family-protein ratios and the degree of apoptosis was observed. We performed flow cytometric analysis of CD34+ cell apoptosis in 59 patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) secondary to MDS (MDS-AML) using annexin V-FITC, which binds to exposed phosphatidylserine on apoptotic cells. Apoptosis was significantly increased in FAB subtypes RA, RARS and RAEB (<10% blasts) (56.5% (15.1-86.5%)) compared to normal controls (18.5% (3.4-33.4%), P<0.0001) and RAEB-t/MDS-AML (16% (2.1-43.2%), P<0.0001). There was no correlation between % apoptosis, Full blood count or cytogenetics in any disease category. Two-colour cytometric analysis of permeabilized CD34+ cells stained with antibodies to Bcl-2, Bcl-X (anti-apoptotic), Bax and Bad (pro-apoptotic), demonstrated significantly higher ratios of pro- v anti-apoptotic proteins in early MDS (2.47 (1.19-9.42) compared to advanced disease (1.14 (0.06-3.32), P=0.0001). Moreover, using repeated measures of variants (ANOVA), we found that variations between individual Bcl-2-related proteins differed significantly according to disease subtype (P<0.0005). Our results confirm that CD34+ cell apoptosis was significantly increased in MDS subtypes RA and RARS and fell with disease progression. Early MDS was also associated with a significantly higher CD34+ cell pro- v anti-apoptotic Bcl-2-family-protein ratio than advanced disease. Furthermore, patterns of expression of individual Bcl-2 related proteins differed significantly between different disease categories. However, no correlation between pro- v anti-apoptotic Bcl-2-family-protein ratios and the degree of apoptosis was observed. We performed flow cytometric analysis of CD34 + cell apoptosis in 59 patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) secondary to MDS (MDS‐AML) using annexin V‐FITC, which binds to exposed phosphatidylserine on apoptotic cells. Apoptosis was significantly increased in FAB subtypes RA, RARS and RAEB (<10% blasts) (56.5% (15.1–86.5%)) compared to normal controls (18.5% (3.4–33.4%), P < 0.0001) and RAEB‐t/MDS‐AML (16% (2.1–43.2%), P < 0.0001). There was no correlation between % apoptosis, Full blood count or cytogenetics in any disease category. Two‐colour cytometric analysis of permeabilized CD34 + cells stained with antibodies to Bcl‐2, Bcl‐X (anti‐apoptotic), Bax and Bad (pro‐apoptotic), demonstrated significantly higher ratios of pro‐ v anti‐apoptotic proteins in early MDS (2.47 (1.19–9.42) compared to advanced disease (1.14 (0.06–3.32), P = 0.0001). Moreover, using repeated measures of variants (ANOVA), we found that variations between individual Bcl‐2‐related proteins differed significantly according to disease subtype ( P < 0.0005). Our results confirm that CD34 + cell apoptosis was significantly increased in MDS subtypes RA and RARS and fell with disease progression. Early MDS was also associated with a significantly higher CD34 + cell pro‐ v anti‐apoptotic Bcl‐2‐family‐protein ratio than advanced disease. Furthermore, patterns of expression of individual Bcl‐2 related proteins differed significantly between different disease categories. However, no correlation between pro‐ v anti‐apoptotic Bcl‐2‐family‐protein ratios and the degree of apoptosis was observed. |
Author | Mufti Pagliuca Fishlock Mijovic Czepulkowski Parker |
Author_xml | – sequence: 1 givenname: J. E surname: PARKER fullname: PARKER, J. E organization: King's College Hospital and School of Medicine and Dentistry, London, United Kingdom – sequence: 2 givenname: K. L surname: FISHLOCK fullname: FISHLOCK, K. L organization: King's College Hospital and School of Medicine and Dentistry, London, United Kingdom – sequence: 3 givenname: A surname: MIJOVIC fullname: MIJOVIC, A organization: King's College Hospital and School of Medicine and Dentistry, London, United Kingdom – sequence: 4 givenname: B surname: CZEPULKOWSKI fullname: CZEPULKOWSKI, B organization: King's College Hospital and School of Medicine and Dentistry, London, United Kingdom – sequence: 5 givenname: A surname: PAGLIUCA fullname: PAGLIUCA, A organization: King's College Hospital and School of Medicine and Dentistry, London, United Kingdom – sequence: 6 givenname: G. J surname: MUFTI fullname: MUFTI, G. J organization: King's College Hospital and School of Medicine and Dentistry, London, United Kingdom |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1618549$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/9886323$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkcGO0zAURS00aOgMfAKSF4hdgl07jrNgASNgQJXYwNpynRfhksTBL502u34CS9jzZf0SnGk1bLFk2dY9911L94pc9KEHQihnOWdSvdrkXKgiW3LJc15VOmecc5nvH5HFg3BBFoyxMksG_YRcIW4Y44IV_JJcVlorsRQL8ud4-LUKu-PhZ_T4_Xj4TbsJ2lBPOLQWR-8oTn0dQwfUI7WIwXk7Qk13fvxGYe8A0d8BtUMYxoAz09dpU9-7CBYTGe3oAw0NHWJIOfQOIm5nbvTpeTLOQWvXpvdy_gq09xnJMILv8Sl53NgW4dn5vCZf37_7cnObrT5_-HjzZpU5KYXMFGu0KGpWlVLrUhaSrbWrkqIsL5VomFZWNaCEKivg0hWyYHzJRd24eg21Fdfk5WluCv6xBRxN59FB29oewhaNqrgo0kqgPoEuBsQIjRmi72ycDGdmLshszNyDmXswc0HmviCzT9bn54ztuoP6wXhuJOkvzrpFZ9sm2t55_DdfcV3IKmGvT9jOtzD9d7x5--l2vom_X1S3VA |
CODEN | BJHEAL |
CitedBy_id | crossref_primary_10_1038_nrc3321 crossref_primary_10_1038_sj_leu_2401959 crossref_primary_10_1182_blood_V95_12_3929_012k01_3929_3938 crossref_primary_10_1182_blood_V96_12_3932_h8003932_3932_3938 crossref_primary_10_1007_BF02826211 crossref_primary_10_1158_1078_0432_CCR_04_0598 crossref_primary_10_1007_BF03032653 crossref_primary_10_1016_j_exphem_2008_07_012 crossref_primary_10_1046_j_1365_2141_2001_02581_x crossref_primary_10_1111_j_1365_2796_2008_02052_x crossref_primary_10_1182_blood_2002_01_0096 crossref_primary_10_1182_bloodadvances_2020004094 crossref_primary_10_1292_jvms_62_1059 crossref_primary_10_1111_j_1582_4934_2003_tb00232_x crossref_primary_10_1182_blood_V96_12_3932 crossref_primary_10_1007_s00277_009_0835_2 crossref_primary_10_1371_journal_pone_0165582 crossref_primary_10_1182_blood_2007_11_122028 crossref_primary_10_1038_s41375_021_01212_6 crossref_primary_10_1002_ajh_10108 crossref_primary_10_1016_j_leukres_2007_04_012 crossref_primary_10_1186_s12867_016_0071_y crossref_primary_10_3109_10428190009054877 crossref_primary_10_3109_10428190109064605 crossref_primary_10_5858_2002_126_0255_TPE crossref_primary_10_5858_2005_129_1299_MSCFPA crossref_primary_10_1016_S0145_2126_02_00098_X crossref_primary_10_1038_sj_leu_2402110 crossref_primary_10_1016_j_leukres_2019_03_006 crossref_primary_10_1634_theoncologist_2011_S3_35 crossref_primary_10_1016_j_leukres_2003_12_004 crossref_primary_10_1016_S0145_2126_99_00152_6 crossref_primary_10_1016_j_yexcr_2015_12_008 crossref_primary_10_1046_j_1365_2141_2001_02708_x crossref_primary_10_1016_S0301_472X_00_00607_X crossref_primary_10_1182_blood_2012_07_445635 crossref_primary_10_1007_s12094_010_0574_9 crossref_primary_10_1016_j_leukres_2009_03_027 crossref_primary_10_1080_10428190400027829 crossref_primary_10_1016_j_blre_2007_10_003 crossref_primary_10_1097_00001622_200001000_00003 crossref_primary_10_1016_j_exphem_2005_02_005 crossref_primary_10_1016_j_blre_2013_07_003 crossref_primary_10_1111_j_1365_2362_2004_01417_x crossref_primary_10_1007_BF02994003 crossref_primary_10_1038_leu_2014_301 crossref_primary_10_1007_s12032_010_9678_x crossref_primary_10_1016_j_arcmed_2003_09_001 crossref_primary_10_1016_S0145_2126_99_00094_6 crossref_primary_10_1038_s41598_018_32306_4 crossref_primary_10_1182_asheducation_2002_1_136 crossref_primary_10_1038_nrclinonc_2017_197 crossref_primary_10_1093_hmg_ddn113 crossref_primary_10_1002_jhm_2049 crossref_primary_10_1016_S0301_472X_00_00179_X crossref_primary_10_1053_j_seminhematol_2007_11_006 crossref_primary_10_1111_bjh_14666 crossref_primary_10_3109_10428190109060340 crossref_primary_10_1182_blood_2004_05_2017 crossref_primary_10_1016_j_cbi_2017_05_014 crossref_primary_10_1139_bcb_2012_0109 crossref_primary_10_1016_j_leukres_2011_06_017 crossref_primary_10_26559_mersinsbd_581124 crossref_primary_10_1182_blood_V95_12_3929 crossref_primary_10_3390_ijms16010966 crossref_primary_10_1016_j_leukres_2011_02_025 crossref_primary_10_1038_sj_leu_2403021 crossref_primary_10_3892_ijo_2016_3689 crossref_primary_10_1182_blood_2002_06_1774 crossref_primary_10_1182_blood_2012_02_412379 crossref_primary_10_1016_S0145_2126_00_00151_X crossref_primary_10_1182_blood_2004_06_2108 crossref_primary_10_1016_j_exphem_2006_08_017 |
Cites_doi | 10.1182/blood.V88.11.4275.4275 10.1182/blood.V89.1.243 10.1016/0022-1759(95)00072-I 10.1038/sj.leu.2400640 10.1111/j.1365-2141.1982.tb02771.x 10.1182/blood.V81.11.3091.3091 10.1182/blood.V88.2.386.bloodjournal882386 10.1111/j.1365-2141.1991.tb08616.x 10.1038/sj.leu.2400980 10.7326/0003-4819-103-4-620 10.1182/blood.V79.5.1291.1291 10.1182/blood.V89.6.2079 10.1002/(SICI)1097-0320(19970901)29:1<28::AID-CYTO2>3.0.CO;2-9 10.1038/sj.leu.2400654 10.1016/S0145-2126(96)00110-5 10.1002/(SICI)1096-9896(199605)179:1<26::AID-PATH516>3.0.CO;2-E 10.3109/10428199709039010 10.1182/blood.V86.1.268.bloodjournal861268 10.1084/jem.182.5.1545 10.1182/blood.V84.5.1415.bloodjournal8451415 |
ContentType | Journal Article |
Copyright | 1999 INIST-CNRS |
Copyright_xml | – notice: 1999 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1046/j.1365-2141.1998.01114.x |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1365-2141 |
EndPage | 1082 |
ExternalDocumentID | 10_1046_j_1365_2141_1998_01114_x 9886323 1618549 BJH1114 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1KJ 1OB 1OC 23N 24P 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6J9 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8F7 8UM 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANLZ AAONW AASGY AAXRX AAYEP AAZKR ABCQN ABCUV ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHEFC AI. AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EGARE EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IH2 IHE IX1 J0M J5H K48 KBYEO L7B LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 V8K V9Y VH1 W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT 08R AAJUZ AAPBV AAVGM ABCVL ABFLS ABHUG ABPTK ABWRO ACXME ADAWD ADDAD ADGIM AFVGU AGJLS IPNFZ IQODW UMP ZA5 CGR CUY CVF ECM EIF NPM AAMNL AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c4434-60f835d09748874540b8c94346a1763f086a6fe63679e14c54501213dfcdbeda3 |
IEDL.DBID | 33P |
ISSN | 0007-1048 |
IngestDate | Fri Aug 16 09:51:29 EDT 2024 Fri Nov 22 00:42:56 EST 2024 Sat Sep 28 08:36:16 EDT 2024 Fri Nov 25 01:03:26 EST 2022 Sat Aug 24 01:03:42 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Human Flow cytometry Fluorescent labelling Cell death Pathogenesis Gene product C-Onc gene Genetics Malignant hemopathy Myelodysplastic syndrome Protooncogene Apoptosis |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4434-60f835d09748874540b8c94346a1763f086a6fe63679e14c54501213dfcdbeda3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doi.org/10.1046/j.1365-2141.1998.01114.x |
PMID | 9886323 |
PQID | 69135555 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_69135555 crossref_primary_10_1046_j_1365_2141_1998_01114_x pubmed_primary_9886323 pascalfrancis_primary_1618549 wiley_primary_10_1046_j_1365_2141_1998_01114_x_BJH1114 |
PublicationCentury | 1900 |
PublicationDate | December 1998 |
PublicationDateYYYYMMDD | 1998-12-01 |
PublicationDate_xml | – month: 12 year: 1998 text: December 1998 |
PublicationDecade | 1990 |
PublicationPlace | Oxford, U.K. and Cambridge, USA |
PublicationPlace_xml | – name: Oxford, U.K. and Cambridge, USA – name: Oxford – name: England |
PublicationTitle | British journal of haematology |
PublicationTitleAlternate | Br J Haematol |
PublicationYear | 1998 |
Publisher | Blackwell Science Ltd Blackwell |
Publisher_xml | – name: Blackwell Science Ltd – name: Blackwell |
References | 1993; 7 1998; 26 1989; 4 1997; 21 1982; 51 1993; 81 1991; 77 1997; 24 1997; 89 1986; 15 1997; 29 1985; 103 1992; 79 1996; 148 1996; 10 1994; 84 1995; 86 1997; 90 1995; 40 1997; 11 1996; 179 1995; 184 1998; 12 1995; 182 1996; 88 Ter‐Harmsel B. (e_1_2_6_27_2) 1996; 179 Krajewska M. (e_1_2_6_19_2) 1996; 148 e_1_2_6_30_2 Lima M. (e_1_2_6_20_2) 1995; 40 Cortelezzi A. (e_1_2_6_9_2) 1996; 88 Yoshida Y. (e_1_2_6_31_2) 1993; 7 Kliche K.O. (e_1_2_6_17_2) 1997; 90 e_1_2_6_18_2 Greenberg P.L. (e_1_2_6_14_2) 1994; 84 e_1_2_6_12_2 e_1_2_6_13_2 e_1_2_6_10_2 e_1_2_6_16_2 De‐Witte T. (e_1_2_6_11_2) 1989; 4 Mufti G.J. (e_1_2_6_22_2) 1986; 15 e_1_2_6_15_2 Stoetzer O.J. (e_1_2_6_26_2) 1996; 10 e_1_2_6_8_2 e_1_2_6_7_2 e_1_2_6_29_2 e_1_2_6_4_2 e_1_2_6_3_2 e_1_2_6_6_2 e_1_2_6_5_2 e_1_2_6_24_2 e_1_2_6_23_2 Traycoff C.M. (e_1_2_6_28_2) 1998; 26 e_1_2_6_2_2 e_1_2_6_21_2 e_1_2_6_25_2 |
References_xml | – volume: 84, start-page: 1415 year: 1994 end-page: 1420 article-title: Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis publication-title: Blood – volume: 11, start-page: 656 year: 1997 end-page: 659 article-title: Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment publication-title: Leukemia – volume: 77, start-page: 497 year: 1991 end-page: 501 article-title: Prognostic factors in adult myelodysplastic syndromes treated by intensive chemotherapy publication-title: British Journal of Haematology – volume: 184, start-page: 39 year: 1995 end-page: 51 article-title: A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V publication-title: Journal of Immunological Methods – volume: 103, start-page: 620 year: 1985 end-page: 625 article-title: Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French–American–British Cooperative Group publication-title: Annals of Internal Medicine – volume: 7, start-page: 144 year: 1993 end-page: 146 article-title: Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome publication-title: Leukemia – volume: 79, start-page: 1291 year: 1992 end-page: 1298 article-title: Bcl‐2 proto‐oncogene expression in normal and neoplastic human myeloid cells publication-title: Blood – volume: 10, start-page: S18 year: 1996 end-page: S22 article-title: Association of bcl‐2, bax, bcl‐xL and interleukin‐1 beta‐converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia publication-title: Leukemia – volume: 12, start-page: 486 year: 1998 end-page: 492 article-title: Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia publication-title: Leukemia – volume: 88, start-page: 386 year: 1996 end-page: 401 article-title: Molecular thanatopsis: a discourse on the BCL2 family and cell death publication-title: Blood – volume: 179, start-page: 26 year: 1996 end-page: 30 article-title: BCL‐2 immunoreactivity increases with severity of CIN: a study of normal cervical epithelia, CIN, and cervical carcinoma publication-title: Journal of Pathology – volume: 81, start-page: 3091 year: 1993 end-page: 3096 article-title: High expression of bcl‐2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy publication-title: Blood – volume: 88, start-page: 4275 year: 1996 end-page: 4287 article-title: Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells publication-title: Blood – volume: 4, start-page: 33 year: 1989 end-page: 35 article-title: Intensive chemotherapy for patients with myelodysplastic syndromes and acute myelogenous leukemia younger than 65 years publication-title: Bone Marrow Transplantation – volume: 89, start-page: 2079 year: 1997 end-page: 2088 article-title: International scoring system for evaluating prognosis in myelodysplastic syndromes publication-title: Blood – volume: 88, start-page: 95a year: 1996 article-title: Apoptosis in myelodysplastic syndromes (MDS): putative role of the Bcl‐2 proto‐oncogene publication-title: Blood – volume: 15, start-page: 953 year: 1986 end-page: 971 article-title: Myelodysplastic syndromes: natural history and features of prognostic importance publication-title: Clinical Haematology – volume: 86, start-page: 268 year: 1995 end-page: 276 article-title: Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes publication-title: Blood – volume: 89, start-page: 243 year: 1997 end-page: 255 article-title: Measurement of spontaneous and therapeutic agent‐induced apoptosis with BCL‐2 protein expression in acute myeloid leukemia publication-title: Blood – volume: 90, start-page: 202a year: 1997 article-title: High expression of phosphatidylserine (PS) in MDS, secondary AML (sAML) and normal pro‐genitors: comparison with primary AML (pAML) publication-title: Blood – volume: 148, start-page: 1567 year: 1996 end-page: 1576 article-title: Immunohistochemical analysis of bcl‐2, bax, bcl‐x, and mcl‐1 expression in prostate cancers publication-title: American Journal of Pathology – volume: 11, start-page: 839 year: 1997 end-page: 845 article-title: Fas/Apo‐1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes publication-title: Leukemia – volume: 84, start-page: 159a year: 1994 article-title: Apoptosis in myelodysplastic syndrome (MDS) publication-title: Blood – volume: 29, start-page: 28 year: 1997 end-page: 33 article-title: Annexin‐V and TUNEL use in monitoring the progression of apoptosis in plants publication-title: Cytometry – volume: 40, start-page: 49 year: 1995 end-page: 52 article-title: Immunophenotypic characteristics of acute leukaemia after myelodysplastic syndromes publication-title: Sangre (Barcelona) – volume: 51, start-page: 189 year: 1982 end-page: 199 article-title: Proposals for the classification of the myelodysplastic syndromes publication-title: British Journal of Haematology – volume: 182, start-page: 1545 year: 1995 end-page: 1556 article-title: Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl‐2 and Abl publication-title: Journal of Experimental Medicine – volume: 24, start-page: 221 year: 1997 end-page: 228 article-title: Bcl‐2 expression in acute myeloblastic leukaemia: relationship with autonomous growth and CD34 antigen expression publication-title: Leukemia and Lymphoma – volume: 26, start-page: 53 year: 1998 end-page: 62 article-title: Proliferation‐induced decline of primitive hematopoietic progenitor cell activity is coupled with an increase in apoptosis of ex vivo expanded CD34 cells publication-title: Experimental Hematology – volume: 21, start-page: 415 year: 1997 end-page: 425 article-title: Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte‐CSF and erythropoietin publication-title: Leukemia Research – ident: e_1_2_6_24_2 doi: 10.1182/blood.V88.11.4275.4275 – ident: e_1_2_6_2_2 doi: 10.1182/blood.V89.1.243 – ident: e_1_2_6_29_2 doi: 10.1016/0022-1759(95)00072-I – volume: 4 start-page: 33 year: 1989 ident: e_1_2_6_11_2 article-title: Intensive chemotherapy for patients with myelodysplastic syndromes and acute myelogenous leukemia younger than 65 years publication-title: Bone Marrow Transplantation contributor: fullname: De‐Witte T. – volume: 10 start-page: S18 year: 1996 ident: e_1_2_6_26_2 article-title: Association of bcl‐2, bax, bcl‐xL and interleukin‐1 beta‐converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia publication-title: Leukemia contributor: fullname: Stoetzer O.J. – volume: 7 start-page: 144 year: 1993 ident: e_1_2_6_31_2 article-title: Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome publication-title: Leukemia contributor: fullname: Yoshida Y. – ident: e_1_2_6_5_2 doi: 10.1038/sj.leu.2400640 – ident: e_1_2_6_3_2 doi: 10.1111/j.1365-2141.1982.tb02771.x – ident: e_1_2_6_8_2 doi: 10.1182/blood.V81.11.3091.3091 – ident: e_1_2_6_30_2 doi: 10.1182/blood.V88.2.386.bloodjournal882386 – ident: e_1_2_6_12_2 doi: 10.1111/j.1365-2141.1991.tb08616.x – ident: e_1_2_6_16_2 doi: 10.1038/sj.leu.2400980 – ident: e_1_2_6_4_2 doi: 10.7326/0003-4819-103-4-620 – ident: e_1_2_6_10_2 doi: 10.1182/blood.V79.5.1291.1291 – volume: 148 start-page: 1567 year: 1996 ident: e_1_2_6_19_2 article-title: Immunohistochemical analysis of bcl‐2, bax, bcl‐x, and mcl‐1 expression in prostate cancers publication-title: American Journal of Pathology contributor: fullname: Krajewska M. – volume: 88 start-page: 95a year: 1996 ident: e_1_2_6_9_2 article-title: Apoptosis in myelodysplastic syndromes (MDS): putative role of the Bcl‐2 proto‐oncogene publication-title: Blood contributor: fullname: Cortelezzi A. – ident: e_1_2_6_13_2 doi: 10.1182/blood.V89.6.2079 – ident: e_1_2_6_23_2 doi: 10.1002/(SICI)1097-0320(19970901)29:1<28::AID-CYTO2>3.0.CO;2-9 – ident: e_1_2_6_6_2 doi: 10.1038/sj.leu.2400654 – volume: 15 start-page: 953 year: 1986 ident: e_1_2_6_22_2 article-title: Myelodysplastic syndromes: natural history and features of prognostic importance publication-title: Clinical Haematology contributor: fullname: Mufti G.J. – volume: 26 start-page: 53 year: 1998 ident: e_1_2_6_28_2 article-title: Proliferation‐induced decline of primitive hematopoietic progenitor cell activity is coupled with an increase in apoptosis of ex vivo expanded CD34+ cells publication-title: Experimental Hematology contributor: fullname: Traycoff C.M. – ident: e_1_2_6_15_2 doi: 10.1016/S0145-2126(96)00110-5 – volume: 179 start-page: 26 year: 1996 ident: e_1_2_6_27_2 article-title: BCL‐2 immunoreactivity increases with severity of CIN: a study of normal cervical epithelia, CIN, and cervical carcinoma publication-title: Journal of Pathology doi: 10.1002/(SICI)1096-9896(199605)179:1<26::AID-PATH516>3.0.CO;2-E contributor: fullname: Ter‐Harmsel B. – volume: 40 start-page: 49 year: 1995 ident: e_1_2_6_20_2 article-title: Immunophenotypic characteristics of acute leukaemia after myelodysplastic syndromes publication-title: Sangre (Barcelona) contributor: fullname: Lima M. – ident: e_1_2_6_7_2 doi: 10.3109/10428199709039010 – ident: e_1_2_6_25_2 doi: 10.1182/blood.V86.1.268.bloodjournal861268 – ident: e_1_2_6_21_2 doi: 10.1084/jem.182.5.1545 – ident: e_1_2_6_18_2 doi: 10.1182/blood.V84.5.1415.bloodjournal8451415 – volume: 84 start-page: 159a year: 1994 ident: e_1_2_6_14_2 article-title: Apoptosis in myelodysplastic syndrome (MDS) publication-title: Blood contributor: fullname: Greenberg P.L. – volume: 90 start-page: 202a year: 1997 ident: e_1_2_6_17_2 article-title: High expression of phosphatidylserine (PS) in MDS, secondary AML (sAML) and normal pro‐genitors: comparison with primary AML (pAML) publication-title: Blood contributor: fullname: Kliche K.O. |
SSID | ssj0013051 |
Score | 1.9494445 |
Snippet | We performed flow cytometric analysis of CD34+ cell apoptosis in 59 patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) secondary to... We performed flow cytometric analysis of CD34 + cell apoptosis in 59 patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) secondary to... |
SourceID | proquest crossref pubmed pascalfrancis wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1075 |
SubjectTerms | Acute Disease acute myeloid leukaemia Adult Aged Aged, 80 and over Annexin A5 - metabolism annexin V Antigens, CD34 - metabolism apoptosis Apoptosis - physiology Bcl‐2 Biological and medical sciences Female Flow Cytometry Hematologic and hematopoietic diseases Humans Leukemia, Myeloid - metabolism Leukemia, Myeloid - pathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Middle Aged myelodysplastic syndrome Myelodysplastic Syndromes - metabolism Myelodysplastic Syndromes - pathology Proto-Oncogene Proteins c-bcl-2 - metabolism |
Title | ‘Low‐risk’ myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro‐ versus anti‐apoptotic bcl‐2‐related proteins |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1046%2Fj.1365-2141.1998.01114.x https://www.ncbi.nlm.nih.gov/pubmed/9886323 https://search.proquest.com/docview/69135555 |
Volume | 103 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NatwwEBZNDqUQkv6FuGlSHXp1sNdjyT42fywhKYW20JuwLAkWUtvEu2Rz20fosb33yfZJMiPbCQs5hJDDwho0a-94NPqkmfmGsc8AkTNS6tBogBBSZ8Pc-vwnY8DikiY1HWWPv8uvv7LjE6LJORtqYTp-iLsDN5oZ3l_TBC9014Uk8uy2Q4ZWDDGV3GUH1DUdDghP4qbBV3Mk3-4DClHaN8-T6Hkg65N6-gDngz-0slJtNEWLSnNdt4uH4OgquvXL0-nWc_6x12yzB6n8S2dVb9gLW71lLy_6MPw79n-5-HteXy8Xfygzfbn4x3_f2Mva3LQNgnEU4gMRAp-0vOgtwBpOp77czqk0Ab0sL5q6mdYtjakMfvikIhDb4khvmLx2HDWA9-GUPTKjcdMJXnaCdCNdXuL1iB6F0vpQ0jNPTKr2Pft5evLjaBz27R7CEiCBUEQO4aCJcIeTEQk_RDorib5OFDF6QYebr0I4KxIh0ZygROznCemMK422pki22XpVV3YHX60AW47ApSMhIdfktqSNSpOKzElndcDi4dWqpmP1UD4aD1S5RupXpH5F6lde_WoesL0VG7gXFIh5IA_Yp8EmFE5RirsUla1nrRJ5jKguTQO23ZnKnWieZSIZJQET3iAe_Szq8GxM3z48VXCXvfLFlT4v5yNbn17N7B5ba81s38-bW-AxHYw |
link.rule.ids | 315,782,786,1408,27933,27934,46064,46488 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Pa9RAFH9oBRXE_8VUa-fgNTXZvMwkR1tbVrstghW8DUlmBhZqEswutrf9CB717ifbT9L3JtmWhR5EPAQ2MC_Jvvzem1_m_RmAN4iRM0qVoSkRQ0ydDXPr85-MQUtTmip5KXv8WZ18zd4fcJuco1UtTN8f4mrBjS3D-2s2cF6QfjuEJXsr9ylaMcZcc5ft8rbpuEuE8g5KwiXXcySfrkMKUTpsn6fI92A2pPUMIc4br7Q2Vz1oi47U5vr9Lm4ipOv81k9Qh4_-6197DA8Hnire9cB6Ards_RTuHg-R-GfwZ7n4NWl-LBc_OTl9ufgtvl3Ys8ZcdC3xcRISq14IYtqJYgCBNYIXfoU95-oEcrSiaJt21nQ8pjZ0iGnNPLajkR6bonGCVED3EZxAMudxsymd9oJ8o7I6o_MRPwpn9pGkbz4xrbvn8OXw4HR_HA47PoQVYoKhjBwxQhPRR07GffgxKrOKO9jJIiZH6Oj7q5DOykQqQhRWRP98TzrjKlNaUySbsFE3tX1B71airUbo0pFUmJfsuZSNKpPKzClnywDi1bvVbd_YQ_uAPHLxGqtfs_o1q1979evzALbXQHAtKIn2YB7AzgoUmqyUQy9FbZt5p2UeE7FL0wA2e6xcieZZJpNREoD0iPjrZ9F7H8f8a-tfBXfg3vj0eKInH06OXsJ9X2vp03Rewcbs-9xuw-3OzF97I7oEzNQhtA |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1fa9RAEB-0QhHE-q8Ybe0--JqaXCa7yaO2Pc5aS0EF35YkuwsHNQnmDtu3-wg-6ruf7D5JZza5loM-iPgQuMBOkpvMzP6yM_NbgNeIkTNKlaEpEUNMnQ1z6-ufjEFLU5oqeSl78kmdfs0Oj5gm53jVC9PzQ1wvuLFn-HjNDt4a92bISvZO7iu0Yoy55S7b513TcZ_w5D0kVM48-klydpNRiNJh9zxFoQezoapnyHDeeqW1qepBW3SkNddvd3EbHl2Ht35-Gm_9z3_2CB4OKFW87c3qMdyx9RPY_Djk4Z_Cn-Xi10nzY7n4yaXpy8Vv8e3SnjfmsmsJjZOQWDEhiGknisEErBG87CvsBfcmUJgVRdu0s6bjMbWhQ0xrRrEdjfSWKRonSAN0H8HlI3MeN5vSaS_INyqrczof8aNwXR9JeuqJad09gy_jo88Hk3DY7yGsEBMMZeQID5qIPnEyZuHHqMwq5q-TRUxh0NHXVyGdlYlUZE9YEfjzjHTGVaa0pki2YaNuavucXq1EW43QpSOpMC85bikbVSaVmVPOlgHEq1er257WQ_t0PHLrGqtfs_o1q1979euLAHbXbOBGUBLowTyAvZVNaPJRTrwUtW3mnZZ5TLAuTQPY7k3lWjTPMpmMkgCkN4i_fhb97njCv178q-AebJ4djvXJ-9MPL-G-b7T0NTo7sDH7Pre7cLcz81feha4AMyIgWg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E2%80%98Low%E2%80%90risk%E2%80%99+myelodysplastic+syndrome+is+associated+with+excessive+apoptosis+and+an+increased+ratio+of+pro%E2%80%90+versus+anti%E2%80%90apoptotic+bcl%E2%80%902%E2%80%90related+proteins&rft.jtitle=British+journal+of+haematology&rft.au=Parker&rft.au=Fishlock&rft.au=Mijovic&rft.au=Czepulkowski&rft.date=1998-12-01&rft.pub=Blackwell+Science+Ltd&rft.issn=0007-1048&rft.eissn=1365-2141&rft.volume=103&rft.issue=4&rft.spage=1075&rft.epage=1082&rft_id=info:doi/10.1046%2Fj.1365-2141.1998.01114.x&rft.externalDBID=10.1046%252Fj.1365-2141.1998.01114.x&rft.externalDocID=BJH1114 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1048&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1048&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1048&client=summon |